Are JAK inhibitors used as an addition to phototherapy for Vitiligo?
For vitiligo, combining treatments often works better than using one alone. Narrowband UVB (NB-UVB) phototherapy is a standard treatment that helps restore skin color. JAK inhibitors, which block the JAK-STAT pathway involved in the immune attack on melanocytes, are now being used alongside phototherapy to boost repigmentation. Research supports this combination approach, though it is still emerging in clinical practice.
What the research says
Phototherapy, especially narrowband UVB (NB-UVB), remains the first-line treatment for vitiligo, but combining it with JAK inhibitors is a growing strategy to improve results 310. A 2024 review notes that JAK inhibitors target the immune pathway that destroys melanocytes, and when used with UV exposure, they may enhance repigmentation 9. Another review highlights that combination therapies including JAK inhibitors are increasingly explored in clinical practice 3. A case report showed that the JAK inhibitor upadacitinib led to significant repigmentation in a patient with extensive vitiligo, though it was used alone, not with phototherapy 2. The approved topical JAK inhibitor ruxolitinib cream is a first-line therapy for non-segmental vitiligo, and it is often used with phototherapy for better results 1011. Overall, the evidence suggests that adding JAK inhibitors to phototherapy can improve outcomes, but more studies are needed to confirm optimal protocols.
What to ask your doctor
- Would combining a JAK inhibitor with narrowband UVB phototherapy be appropriate for my type and extent of vitiligo?
- What are the potential benefits and risks of adding a JAK inhibitor to my current phototherapy regimen?
- Are there any specific JAK inhibitors (topical or oral) that have been studied for use with phototherapy in vitiligo?
- How long might it take to see repigmentation with this combination, and how will we monitor progress?
- Should I be screened for hepatitis B before starting a JAK inhibitor, given the increased reactivation risk?
This question is drawn from common patient questions about Dermatology and answered using cited medical research. We do not provide individualized advice.